Massive study launches to unravel mysteries of rare lymphatic diseases
NCT ID NCT05731141
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 5 times
Summary
This natural history study aims to collect data from 1,200 people with lymphatic anomalies—rare conditions affecting the body's lymph system—over many years. Researchers will track symptoms, perform genetic testing, and gather biospecimens to better understand why these conditions develop. The goal is to improve future treatments, not to test a new therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could provide crucial insights into how lymphatic anomalies develop and progress, paving the way for better treatments in the future.
- What could go wrong
- This is an observational study, not a treatment trial, so there is no direct benefit to participants. It may take many years to gather enough data to influence clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHATIC ABNORMALITIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Philadelphia
NOT_YET_RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody boost chemotherapy against a rare leukemia?
- Tiny nodules in connective tissue may reveal hidden clues about organ health
- Supercharged immune cells aim to stop lymphoma comeback
- Unlicensed cord blood units tested for safety in blood cancer patients
- Engineered immune cells take aim at tough lymphomas in first human test
- Engineered immune cells with an emergency brake tested in lymphoma